Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended		170 Months Ended		9 Months Ended			9 Months Ended	0 Months Ended		1 Months Ended		1 Months Ended					0 Months Ended	8 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013 Stock options	Sep. 30, 2013 Research and Development Agreements MDACC	Dec. 31, 2012 Research and Development Agreements MDACC	Sep. 30, 2013 Research and Development Agreements PerkinElmer Health Sciences, Inc.	Apr. 25, 2013 Research and Development Agreements PerkinElmer Health Sciences, Inc. HCC Field	Apr. 25, 2013 Research and Development Agreements PerkinElmer Health Sciences, Inc. Other fields	Jun. 30, 2013 Research and Development Agreements Illumina	Aug. 31, 2013 Research and Development Agreements USC	Jan. 31, 2013 Employment agreement with Mark Erlander, Ph.D.	Jan. 31, 2013 Employment agreement with Mark Erlander, Ph.D. Maximum	Jan. 31, 2013 Employment agreement with Mark Erlander, Ph.D. Stock options	Jul. 31, 2013 Public Offering and Controlled Equity Offering	Jan. 25, 2013 Public Offering and Controlled Equity Offering Maximum	Jan. 25, 2013 Public Offering and Controlled Equity Offering Agent	Sep. 30, 2013 Public Offering and Controlled Equity Offering Agent	Jan. 25, 2013 Public Offering and Controlled Equity Offering Agent Maximum	Jun. 30, 2013 CFO	Jun. 30, 2013 CFO Stock options	Jun. 30, 2013 CEO	Jun. 30, 2013 CEO Stock options
Commitments and contingencies
Amount committed to be paid									$ 152,900					$ 232,000
Research and development expense	915,457	511,433	2,661,551	1,326,197	20,111,002			107,740		57,000
Period from the end of proof of principle work on certain fields within which the exclusive option is exercisable											15 days	15 days
Period to negotiate a license agreement if the exclusive option is exercised											60 days	60 days
Period during which the license agreement must first be offered to PerkinElmer											1 year
Compensation per year															200,000								220,000		350,000
Receipt of milestone payments										90,000
Period of termination of agreement, after completion of the Research Plan													30 days
Period of termination of agreement, on its anniversary unless extended by mutual written agreement													1 year
Bonus as percentage of base salary																50.00%
Award granted (in shares)							710,427										200,000							60,000		200,000
Exercise price of award granted (in dollars per share)							$ 6.69										$ 7.04							$ 6.00		$ 6.00
Vesting period of options																	4 years							4 years		4 years
Period of base compensation which would be received as severance payment															6 months
Aggregate initial offering price																			150,000,000			30,000,000
Commission as percentage of gross proceeds																				3.00%
Gross proceeds from sale of shares																		$ 15,000,000			$ 4,200,000
Number of shares sold	18,891,949		18,891,949		18,891,949	15,478,177												2,142,857			488,476